Partial factor IXa inhibition with TTP889 for prevention of venous thromboembolism: An exploratory study

Journal of Thrombosis and Haemostasis

Volumn 6, Issue 3, 2008, Pages 457-463

  Eriksson, Bengt I ^a   Dahl, O E ^b   Lassen, M R ^c   Ward, D P ^d   Rothlein, R ^d   Davis, G ^c   Turpie, A G G ^e  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b THROMBOSIS RESEARCH INSTITUTE   (United Kingdom)

^c Hoersholm Hospital   (Denmark)

^d TransTech Pharma Inc   (United States)

^e HHS General Hospital   (Canada)

Author keywords

Factor IXa inhibitor; Hip fracture surgery; Oral anticoagulant; TTP889; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 9A; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; TTP 889; UNCLASSIFIED DRUG;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HIP FRACTURE; HIP SURGERY; HUMAN; INCIDENCE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; MULTICENTER STUDY; PHLEBOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STEADY STATE; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM;

ADULT; AGED; AGED, 80 AND OVER; DOUBLE-BLIND METHOD; FACTOR IXA; FEMALE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PHLEBOGRAPHY; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 39549104685     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2007.02872.x     Document Type: Article

References (29)

1. Eriksson BI, Quinlan DJ. Oral anticoagulants in development: Focus on thromboprophylaxis in patients undergoing orthopaedic surgery. Drugs 2006; 66: 1411-29.
2. Weitz JI. Emerging anticoagulants for the treatment of venous thromboembolism. Thromb Haemost 2006; 96: 274-84.
3. Davie EW, Fujikawa K. Basic mechanisms in blood coagulation. Annu Rev Biochem 1975; 44: 799-829.
4. Hoffman M, Monroe DM. Coagulation 2006: A modern view of hemostasis. Hematol Oncol Clin North Am 2007; 21: 1-11.
5. Osterud B, Rapaport SI. Activation of factor IX by the reaction product of tissue factor and factor VII: Additional pathway for initiating blood coagulation. Proc Natl Acad Sci USA 1977; 74: 5260-4.
6. Benedict CR, Ryan J, Wolitzky B, Ramos R, Gerlach M, Tijburg P, Stern D. Active site-blocked factor IXa prevents intravascular thrombus formation in the coronary vasculature without inhibiting extravascular coagulation in a canine thrombosis model. J Clin Invest 1991; 88: 1760-5.
7. Spanier TB, Oz MC, Minanov OP, Simantov R, Kisiel W, Stern DM, Rose EA, Schmidt AM. Heparinless cardiopulmonary bypass with active-site blocked factor IXa: A preliminary study on the dog. J Thoracic Cardiovasc Surg 1998; 115: 1179-88.
8. Feuerstein GZ, Patel A, Toomey JR, Bugelski P, Nichols AJ, Church WR, Valocik R, Koster P, Baker A, Blackburn MN. Antithrombotic efficacy of a novel murine antihuman factor IX antibody in rats. Arterioscler Thromb Vasc Biol 1999; 19: 2554-62.
9. Toomey JR, Valocik RE, Koster PF, Gabriel MA, McVey M, Hart TK, Ohlstein EH, Parsons AA, Barone FC. Inhibition of factor IX(a) is protective in a rat model of thromboembolic stroke. Stroke 2002; 33: 578-85.
10. Rusconi CP, Scardino E, Layzer J, Pitoc GA, Ortel TL, Monroe D, Sullenger BA. RNA aptamers as reversible antagonists of coagulation factor IXa. Nature 2002; 419: 90-4.
11. Dyke CK, Steinhubl SR, Kleiman NS, Cannon RO, Aberle LG, Lin M, Myles SK, Melloni C, Harrington RA, Alexander JH, Becker RC, Rusconi CP. First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: A phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity. Circulation 2006; 114: 2490-7.
12. Spanier TB, Chen JM, Oz MC, Edwards NM, Kisiel W, Stern DM, Rose EA, Schmidt AM. Selective anticoagulation with active site-blocked factor IXA suggests separate roles for intrinsic and extrinsic coagulation pathways in cardiopulmonary bypass. J Thorac Cardiovasc Surg 1998; 116: 860-9.
13. Refino CJ, Jeet S, DeGuzman L, Bunting S, Kirchhofer D. A human antibody that inhibits factor IX/IXa function potently inhibits arterial thrombosis without increasing bleeding. Arterioscler Thromb Vasc Biol 2002; 22: 517-22.
14. Thompson AR, Chen SH. Characterization of factor IX defects in hemophilia B patients. Methods Enzymol 1993; 222: 143-69.
15. Sramek A, Kriek M, Rosendaal FR. Decreased mortality of ischaemic heart disease among carriers of haemophilia. Lancet 2003; 362: 351-4.
16. Muntean W, Leschnik B. Factor VIII influences binding of factor IX and factor X to intact human platelets. Thromb Res 1989; 55: 537-48.
17. Ahmad SS, London FS, Walsh PN. Binding studies of the enzyme (factor IXa) with the cofactor (factor VIIIa) in the assembly of factor-X activating complex on the activated platelet surface. J Thromb Haemost 2003; 1: 2348-55.
18. Rothlein R, Shen JM, Naser N, Gohimukkula DR, Caligan TB, Andrews RC, Schmidt AM, Rose EA, Mjalli AMM. TTP889, a novel orally active partial inhibitor of FIXa inhibits clotting in two a/v shunt models without prolonging bleeding times. (Abstract). Blood 2005; 106: A1886.
19. Dahl OE. Orthopaedic surgery as a model for drug development in thrombosis. Drugs 2004; 64 (Suppl. 1): 17-25.
20. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Prevention of venous thromboembolism: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (Suppl.): 338S-400S.
21. Eriksson BI, Lassen MR. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: A multicenter, randomized, placebo-controlled, double-blind study. Arch Intern Med 2003; 163: 1337-42.
22. Rabinov K, Paulin S. Roentgen diagnosis of venous thrombosis in the leg. Arch Surg 1972; 104: 134-44.
23. Kalebo P, Ekman S, Lindbratt S, Eriksson BI, Pauli U, Zachrisson BE, Close P. Percentage of inadequate phlebograms and observer agreement in thromboprophylactic multicenter trials using standardized methodology and central assessment. Thromb Haemost 1996; 76: 893-6.
24. Kalebo P, Anthmyr BA, Eriksson BI, Zachrisson BE. Optimization of ascending phlebography of the leg for screening of deep vein thrombosis in thromboprophylactic trials. Acta Radiol 1997; 38: 320-6.
25. Howard EL, Becker KC, Rusconi CP, Becker RC. Factor IXa Inhibitors as Novel Anticoagulants. R1 Howard Factor IXa Inhibitors. Arterioscler Thromb Vasc Biol 2007; 24: 722-7.
26. Eriksson BI, Bauer KA, Lassen MR, Turpie AGG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. New Engl J Med 2001; 345: 1298-304.
27. Arnesen H, Dahl OE, Aspelin T, Seljeflot I, Kierulf P, Lyberg T. Sustained prothrombotic profile after hip replacement surgery: The influence of prolonged prophylaxis with dalteparin. J Thromb Haemost 2003; 1: 971-5.
28. Dahl OE, Aspelin T, Arnesen H, Seljeflot I, Kierulf P, Ruyter R, Lyberg T. Increased activation of coagulation and formation of late deep venous thrombosis following discontinuation of thromboprophylaxis after hip replacement surgery. Thromb Res 1995; 80: 299-306.
29. Galster H, Kolb G, Kohsytorz A, Seidlmayer C, Paal V. The pre-, peri-, and postsurgical activation of coagulation and the thromboembolic risk for different risk groups. Thromb Res 2000; 100: 381-8.